A Randomized Double-Blind, Placebo-Controlled Trial of Minocycline in Children and Adolescents with Fragile X Syndrome
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Minocycline rescued synaptic abnormalities and improved behavior in the fragile X mouse model. Previous open-label human studies demonstrated benefits in individuals with fragile X syndrome (FXS); however, its efficacy in patients with FXS has not been assessed in a controlled trial. METHOD: Randomized, double-blind, placebo-controlled, crossover trial in individuals with FXS, aged 3.5 years to 16 years (n = 55, mean age 9.2 [SD, 3.6] years). Participants were randomized to minocycline or placebo for 3 months and then switched to the other treatment. RESULTS: Sixty-nine subjects were screened and 66 were randomized. Fifty-five subjects (83.3%) completed at least the first period and 48 (72.7%) completed the full trial. Intention-to-treat analysis demonstrated significantly greater improvements in one primary outcome, Clinical Global Impression Scale-Improvement after minocycline compared with placebo (2.49 ± 0.13 and 2.97 ± 0.13, respectively, p = .0173) and greater improvement in ad hoc analysis of anxiety and mood-related behaviors on the Visual Analog Scale (minocycline: 5.26 cm ± 0.46 cm, placebo: 4.05 cm ± 0.46 cm; p = .0488). Side effects were not significantly different during the minocycline and placebo treatments. No serious adverse events occurred on minocycline. Results may be potentially biased by study design weaknesses, including unblinding of subjects when they completed the study, drug-related side effects unblinding, and preliminary efficacy analysis results known to investigators. CONCLUSIONS: Minocycline treatment for 3 months in children with FXS resulted in greater global improvement than placebo. Treatment for 3 months appears safe; however, longer trials are indicated to further assess benefits, side effects, and factors associated with a clinical response to minocycline.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Reduction of MMP-9 levels with minocycline in humans with FXS (Dziembowska et al., 2013) contributes to reversal of several FXS phenotypes, including behavioral deficits and enhanced auditory electrocortical activity in adults and/or adolescents with FXS (Paribello et al., 2010; Leigh et al., 2013; Schneider et al., 2013).”
From The Perineuronal ‘Safety’ Net? Perineuronal Net Abnormalities in Neurological Disorders (2018) · cites this paper as Leigh et al., 2013
Experimental — accuracy not yet measuredIn the citing paper
“In a randomized double-blind, placebo-controlled trial in children and adolescents with FXS, three months of minocycline treatment improved anxiety and mood-related behaviours238.”
From Immune mediators in the brain and peripheral tissues in autism spectrum disorder (2015) · cites this paper as [238]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wechsler Abbreviated Scale of Intelligence
Dumont, R., Willis, J. O., Veizel, K., & Zibulsky, J. (2014) · Encyclopedia of Special Education · doi:10.1002/9781118660584.ese2519 · Cited by 5,521
How Matrix Metalloproteinases Regulate Cell Behavior
Sternlicht, M. D., & Werb, Z. (2001) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.17.1.463 · Cited by 3,959
Mullen Scales of Early Learning
Bradley-Johnson, S. (1997) · Psychology in the Schools · doi:10.1002/(sici)1520-6807(199710)34:4<379::aid-pits14>3.0.co;2-e · Cited by 2,325
FMRP Stalls Ribosomal Translocation on mRNAs Linked to Synaptic Function and Autism
Darnell, J. C., Van Driesche, S. J., Zhang, C., Hung, K. Y. S., Mele, A., Fraser, C. E., Stone, E. F., Chen, C., Fak, J. J., Chi, S. W., et al. (2011) · Cell · doi:10.1016/j.cell.2011.06.013 · Cited by 2,072
Stanford-Binet Intelligence Scale
(2012) · SpringerReference · doi:10.1007/springerreference_70151 · Cited by 1,664
Yrjänheikki, J., Tikka, T., Keinänen, R., Goldsteins, G., Chan, P. H., & Koistinaho, J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.23.13496 · Cited by 1,038
Dumont, R., & Willis, J. O. (2008) · Encyclopedia of Special Education · doi:10.1002/9780470373699.speced0804 · Cited by 946
de Boer, A. G. E. M., van Lanschot, J. J. B., Stalmeier, P. F. M., van Sandick, J. W., Hulscher, J. B. F., de Haes, J. C. J. M., & Sprangers, M. A. G. (2004) · Quality of Life Research · doi:10.1023/b:qure.0000018499.64574.1f · Cited by 743
Jacquemont, S., Curie, A., des Portes, V., Torrioli, M. G., Berry-Kravis, E., Hagerman, R. J., Ramos, F. J., Cornish, K., He, Y., Paulding, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001708 · Cited by 609
Self-citationBilousova, T. V., Dansie, L., Ngo, M., Aye, J., Charles, J. R., Ethell, D. W., & Ethell, I. M. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2008.061796 · Cited by 465
A pilot open label, single dose trial of fenobam in adults with fragile X syndrome
Berry-Kravis, E., Hessl, D., Coffey, S., Hervey, C., Schneider, A., Yuhas, J., Hutchison, J., Snape, M., Tranfaglia, M., Nguyen, D. V., et al. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2008.063701 · Cited by 411
Self-citationStanford‐Binet Intelligence Scales
Kamphaus, R. W., & Juechter, J. I. (2010) · The Corsini Encyclopedia of Psychology · doi:10.1002/9780470479216.corpsy0941 · Cited by 385
Safety of doxycycline and minocycline: A systematic review
Smith, K., & Leyden, J. J. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.09.005 · Cited by 352
Tassone, F., Pan, R., Amiri, K., Taylor, A. K., & Hagerman, P. J. (2008) · The Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2008.070073 · Cited by 350
Self-citationThe fragile X prevalence paradox
Hagerman, P. J. (2008) · Journal of Medical Genetics · doi:10.1136/jmg.2008.059055 · Cited by 342
Berry-Kravis, E. M., Hessl, D., Rathmell, B., Zarevics, P., Cherubini, M., Walton-Bowen, K., Mu, Y., Nguyen, D. V., Gonzalez-Heydrich, J., Wang, P. P., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004214 · Cited by 328
Self-citationMinocycline as a Neuroprotective Agent
Stirling, D. P., Koochesfahani, K. M., Steeves, J. D., & Tetzlaff, W. (2005) · The Neuroscientist · doi:10.1177/1073858405275175 · Cited by 279
Prospects for Minocycline Neuroprotection
Plane, J. M., Shen, Y., Pleasure, D. E., & Deng, W. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.191 · Cited by 276
Qin, M., Kang, J., Burlin, T. V., Jiang, C., & Smith, C. B. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.0093-05.2005 · Cited by 263
Aman, M. G., Wh, B., & WOLFORD, P. L. (1995) · PubMed · Cited by 240
Open-label add-on treatment trial of minocycline in fragile X syndrome.
Paribello, C., Tao, L., Folino, A., Berry-Kravis, E., Tranfaglia, M., Ethell, I. M., & Ethell, D. W. (2010) · BMC Neurology · doi:10.1186/1471-2377-10-91 · Cited by 223
Open-Label Treatment Trial of Lithium to Target the Underlying Defect in Fragile X Syndrome
Berry-Kravis, E., Sumis, A., Hervey, C., Nelson, M., Porges, S. W., Weng, N., Weiler, I. J., & Greenough, W. T. (2008) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/dbp.0b013e31817dc447 · Cited by 215
Influence of matrix metalloproteinase MMP-9 on dendritic spine morphology
Michaluk, P., Wawrzyniak, M., Alot, P., Szczot, M., Wyrembek, P., Mercik, K., Medvedev, N., Wilczek, E., De Roo, M., Zuschratter, W., et al. (2011) · Journal of Cell Science · doi:10.1242/jcs.090852 · Cited by 214
Altered mTOR signaling and enhanced CYFIP2 expression levels in subjects with fragile X syndrome
Hoeffer, C. A., Sanchez, E., Hagerman, R. J., Mu, Y., Nguyen, D. V., Wong, H., Whelan, A. M., Zukin, R. S., Klann, E., & Tassone, F. (2012) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2012.00768.x · Cited by 198
Self-citationSansone, S. M., Widaman, K. F., Hall, S. S., Reiss, A. L., Lightbody, A., Kaufmann, W. E., Berry-Kravis, E., Lachiewicz, A., Brown, E. C., & Hessl, D. (2012) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-011-1370-2 · Cited by 176
Self-citationPrevalence of the fragile X syndrome in African‐Americans
Crawford, D. C., Meadows, K. L., Newman, J. L., Taft, L. F., Scott, E., Leslie, M., Shubek, L., Holmgreen, P., Yeargin‐Allsopp, M., Boyle, C., et al. (2002) · American Journal of Medical Genetics · doi:10.1002/ajmg.10427 · Cited by 147
Mechanism-based approaches to treating fragile X
Dölen, G., Carpenter, R. L., Ocain, T. D., & Bear, M. F. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.02.008 · Cited by 136
Rotschafer, S. E., Trujillo, M. S., Dansie, L. E., Ethell, I. M., & Razak, K. A. (2012) · Brain Research · doi:10.1016/j.brainres.2011.12.041 · Cited by 130
De Rubeis, S., & Bagni, C. (2010) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2009.09.013 · Cited by 126
Toward the Validation of Visual Analogue Scale for Anxiety
Facco, E., Zanette, G., Favero, L., Bacci, C., Sivolella, S., Cavallin, F., & Manani, G. (2011) · Anesthesia Progress · doi:10.2344/0003-3006-58.1.8 · Cited by 121
Utari, A., Chonchaiya, W., Rivera, S. M., Schneider, A., Hagerman, R. J., Faradz, S. M. H., Ethell, I. M., & Nguyen, D. V. (2010) · American Journal on Intellectual and Developmental Disabilities · doi:10.1352/1944-7558-115.5.433 · Cited by 105
Self-citationFragile X Syndrome and Targeted Treatment Trials
Hagerman, R., Lauterborn, J., Au, J., & Berry-Kravis, E. (2012) · Results and Problems in Cell Differentiation · doi:10.1007/978-3-642-21649-7_17 · Cited by 103
Self-citationMetz, L., Li, D., Traboulsee, A., Myles, M., Duquette, P., Godin, J., Constantin, M., & Yong, V. (2009) · Multiple Sclerosis Journal · doi:10.1177/1352458509106779 · Cited by 98
Minocycline for Huntington’s disease: An open label study
Bonelli, R. M., Heuberger, C., & Reisecker, F. (2003) · Neurology · doi:10.1212/01.wnl.0000049936.85487.7a · Cited by 86
Siller, S. S., & Broadie, K. (2011) · Disease Models & Mechanisms · doi:10.1242/dmm.008045 · Cited by 86
Watkins, M. W., Kush, J. C., & Glutting, J. J. (1997) · Psychology in the Schools · doi:10.1002/(sici)1520-6807(199710)34:4<309::aid-pits2>3.0.co;2-g · Cited by 63
Benedetto, M. D., Lindner, H., Hare, D. L., & Kent, S. (2005) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2005.06.070 · Cited by 26
Nonverbal Intellectual Assessment of Hispanic and Speech-Impaired Adolescents
Flemmer, D. D., & Roid, G. H. (1997) · Psychological Reports · doi:10.2466/pr0.1997.80.3c.1115 · Cited by 8
Cited by
Hagerman, R. J., Berry-Kravis, E., Hazlett, H. C., Bailey, D. B., Moine, H., Kooy, R. F., Tassone, F., Gantois, I., Sonenberg, N., Mandel, J. L., et al. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.65 · Cited by 838
Self-citationGenetic studies in intellectual disability and related disorders
Vissers, L. E. L. M., Gilissen, C., & Veltman, J. A. (2016) · Nature Reviews Genetics · doi:10.1038/nrg3999 · Cited by 761
Drug repurposing: a promising tool to accelerate the drug discovery process
Parvathaneni, V., Kulkarni, N. S., Muth, A., & Gupta, V. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.06.014 · Cited by 597
Immune mediators in the brain and peripheral tissues in autism spectrum disorder
Estes, M. L., & McAllister, A. K. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3978 · Cited by 514
Conflicts of interest: none declared
Suga, H., Eto, H., Inoue, K., Aoi, N., Kato, H., Araki, J., Higashino, T., Yoshimura, K., Yoshimura, K., Publication, A. F., et al. (2009) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.002.0007 · Cited by 442
Metadata
- Authors
- Leigh, M. J. S., Nguyen, D. V., Mu, Y., Winarni, T. I., Schneider, A., Chechi, T., Polussa, J., Doucet, P., Tassone, F., Rivera, S. M., Hessl, D., & Hagerman, R. J.
- Affiliations
- University of California Davis Medical Center (US)
- University of California, Davis (US)
- Diponegoro University (ID)
- Corresponding author
- Leigh, Mary Jacena S.
- Schneider, Andrea
- Chechi, Tasleem
- Polussa, Jonathan
- Hessl, David
- Hagerman, Randi J.
- ORCID
- Venue
- Journal of Developmental & Behavioral Pediatrics
- Published
- 2013-04
- Volume
- 34
- Issue
- 3
- Pages
- 147-155
- ISSN
- 0196-206X (ISSN-L)
- PMC
- PMC3706260
- OpenAlex
- W2159857276
- Cited by
- 298
- References
- 37
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 12 · 2023: 7 · 2022: 18 · 2021: 10 · 2020: 48 · 2019: 21 · 2018: 19 · 2017: 35 · 2016: 40 · 2015: 28 · 2014: 32 · 2013: 15
- FWCI
- 25.44
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Journal of Developmental & Behavioral Pediatrics (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR000002)
- University of California, Davis
- National Institute of Mental Health (T32MH073124)
- National Center for Research Resources (UL1RR024146)
- National Center for Advancing Translational Sciences
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (HD 02274, P30HD002274)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Life Sciences › Neuroscience › Developmental Neuroscience › Williams Syndrome Research
- Keywords
- minocycline, fragile X syndrome, children and adolescents, anxiety, mood, Clinical Global Impression Scale, treatment efficacy, drug safety, synaptic abnormalities
- MeSH terms
- Adolescent, Child, Child, Preschool, Double-Blind Method, Female, Fragile X Syndrome, Humans, Intelligence, Male, Minocycline, Psychiatric Status Rating Scales, Psychological Tests, Treatment Outcome, Cross-Over Studies, Neuroprotective Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.